TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2015

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.

Chris D Poole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.